摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氯-5-氨基-6-肼基嘧啶 | 42786-59-4

中文名称
4-氯-5-氨基-6-肼基嘧啶
中文别名
4-氯-6-肼基嘧啶-5-胺;4-氯-6-肼基-嘧啶-5-基胺
英文名称
4-chloro-6-hydrazinylpyrimidin-5-amine
英文别名
4-chloro-6-hydrazino-pyrimidin-5-ylamine;4-Chlor-5-amino-6-hydrazino-pyrimidin;4-Chlor-5-amino-6-hydrazinopyrimidin;5-Amino-4-chlor-6-hydrazinopyrimidin
4-氯-5-氨基-6-肼基嘧啶化学式
CAS
42786-59-4
化学式
C4H6ClN5
mdl
MFCD04035542
分子量
159.578
InChiKey
ROYDODCAYOBXEU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    184 °C
  • 沸点:
    255.4±50.0 °C(Predicted)
  • 密度:
    1.87±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    89.8
  • 氢给体数:
    3
  • 氢受体数:
    5

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2933990090

SDS

SDS:cac18e3ea2b83501dd5f4bfc1c558f8a
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    原甲酸三乙酯4-氯-5-氨基-6-肼基嘧啶盐酸 作用下, 以71%的产率得到5-chloro-1,2-dihydropyrimido<5,4-e>-1,2,4-triazine
    参考文献:
    名称:
    吡啶并[3,2- e ] [1,2,4]三嗪的Niementowski型合成:吡啶并[2,3- b ]吡嗪杀真菌剂的强氮杂类似物
    摘要:
    已发现新型三取代的吡啶并[3,2- e ] [1,2,4]三嗪具有与相应的吡并吡嗪杀真菌剂相似的针对重要植物病原体的生物学活性,例如重要的致病性小麦霉菌(Mycosphaerella graminicola)(小麦叶片斑点病),稻瘟病菌(Magnaporthe grisea)(稻瘟病)。以及茄枯萎病(Rhizoctonia solani)。它们是由Niementowski型环缩合首次由单环三嗪制备的。
    DOI:
    10.1016/j.tetlet.2010.03.032
  • 作为产物:
    描述:
    4,6-二氯-5-氨基嘧啶 作用下, 以89%的产率得到4-氯-5-氨基-6-肼基嘧啶
    参考文献:
    名称:
    吡啶并[3,2- e ] [1,2,4]三嗪的Niementowski型合成:吡啶并[2,3- b ]吡嗪杀真菌剂的强氮杂类似物
    摘要:
    已发现新型三取代的吡啶并[3,2- e ] [1,2,4]三嗪具有与相应的吡并吡嗪杀真菌剂相似的针对重要植物病原体的生物学活性,例如重要的致病性小麦霉菌(Mycosphaerella graminicola)(小麦叶片斑点病),稻瘟病菌(Magnaporthe grisea)(稻瘟病)。以及茄枯萎病(Rhizoctonia solani)。它们是由Niementowski型环缩合首次由单环三嗪制备的。
    DOI:
    10.1016/j.tetlet.2010.03.032
点击查看最新优质反应信息

文献信息

  • Triazolopyrimidine cannabinoid receptor 1 antagonists
    申请人:Wu Gang
    公开号:US20060287341A1
    公开(公告)日:2006-12-21
    The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R 1 , R 2 , R 3 , R 4 and R 5 are described herein.
    本申请描述了根据公式I和II的化合物,包括至少一种符合公式I或II的化合物的药物组合物,以及可选地包括一种或多种额外治疗剂的药物组合物,并且使用根据公式I和II的化合物进行治疗的方法,无论是单独使用还是与一种或多种额外治疗剂结合使用。这些化合物具有以下一般公式:包括所有的前药、溶剂化合物、药用可接受盐和立体异构体,其中R1、R2、R3、R4和R5如本文所述。
  • [EN] INHIBITORS OF CELLULAR METABOLIC PROCESSES<br/>[FR] INHIBITEURS DE PROCESSUS MÉTABOLIQUES CELLULAIRES
    申请人:AGIOS PHARMACEUTICALS INC
    公开号:WO2018039972A1
    公开(公告)日:2018-03-08
    The invention provides inhibitor compounds of MAT2A that are useful as therapeutic agents for treating malignancies wherein the compounds have the general formula (I) : wherein ring A, ring B, ring C and, R1 are as described herein.
    该发明提供了MAT2A的抑制剂化合物,可作为治疗恶性肿瘤的治疗剂。这些化合物具有一般公式(I):其中环A、环B、环C和R1如本文所述。
  • [EN] FUNGICIDES BASED ON NITROGEN-CONTAINING HETEROCYCLES<br/>[FR] FONGICIDES A BASE D'HETEROCYCLES CONTENANT DE L'AZOTE
    申请人:SYNGENTA LTD
    公开号:WO2004056829A1
    公开(公告)日:2004-07-08
    Fungicidal compounds having the general formula (1): formula (1) wherein W, Z and one of X and Y are N and the other one of X and Y is CR8; R8 is H, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio or halo(C1-4)alkyl; R and R2 are independently H, halo, C1-8 alkyl, C1-8 alkoxy, C1-8 alkylthio, C2-8 alkenyl, C2-8 alkynyl, cyano or NR3R4, provided that at least one of R and R2 is NR3R4; R1 is halo, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkyl(C1-6)­-alkyl, C1-8 alkoxy, C1-8 alkylthio, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, aryl(C1-4)alkyl, aryl(C1-4)alkoxy, heteroaryl(C1-4)alkyl, heteroaryl­(C1-4)alkoxy, aryl(C1-4)alkylthio, heteroaryl(C1-4)alkylthio, morpholino, piperidino or pyrrolidino; R3 and R4 are independently H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aryl, aryl(C1-8)­- alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl(C1-6)alkyl, heteroaryl, heteroaryl(C1-8)alkyl, NR5R6, provided that not both R3 and R4 are H or NR5R6, or R3 and R4 together form a C3-7 alkylene or C3-7 alkenylene chain optionally substituted with one or more C1-4 alkyl or C1-4 alkoxy groups, or, together with the nitrogen atom to which they are attached, R3 and R4 form a morpholine, thiomorpholine, thiomorpholine S-oxide or thiomorpholine S-dioxide ring or a piperazine or piperazine N-(C1-4)alkyl (especially N-methyl) ring; and R5 and R6 are independently H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aryl, aryl(C1-8)­alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl(C1-6)alkyl, heteroaryl or heteroaryl(C1-8)alkyl; any of the foregoing alkyl, alkenyl, alkynyl or cycloalkyl groups or moieties (other than for R8) being optionally substituted with halogen, cyano, C1-6 alkoxy, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 haloalkoxy, C1-6 alkylthio, tri(C1-4)alkylsilyl, C1-6 alkylamino or C1-6 dialkylamino, any of the foregoing morpholine, thiomorpholine, piperidine, piperazine and pyrrolidine rings being optionally substituted with C1-4 alkyl (especially methyl), and any of the foregoing aryl or heteroaryl groups or moieties being optionally substituted with one or more substituents selected from halo, hydroxy, mercapto, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, halo(C1-6)alkyl, halo(C1-6)alkoxy, C1-6 alkylthio, halo(C1-6)alkylthio, hydroxy(C1-6)alkyl, C1-4 alkoxy(C1-6)alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl(C1-4)alkyl, phenoxy, benzyloxy, benzoyloxy, cyano, isocyano, thiocyanato, isothiocyanato, nitro, -NR''R'', NHCOR'', -NHCONR''R'', -CONR''R'', -SO2R'', -OSO2R'', -COR'', -CR''=NR'' or -N=CR ''R'', in which R'' and R'' are independently hydrogen, C1-4 alkyl, halo-(C1-4)alkyl, C1-4 alkoxy, halo(C1-4)alkoxy, C1-4 alkylthio, C3-6 cycloalkyl, C3-6 cycloalkyl(C1-4)alkyl, phenyl or benzyl, the phenyl and benzyl groups being optionally substituted with halogen, C1-4 alkyl or C1-4 alkoxy.
    具有通式(1)的杀真菌化合物:式(1)其中W,Z和X和Y中的另一个是N,另一个是CR8;R8是H,卤素,C1-4烷基,C1-4烷氧基,C1-4烷基基或卤代(C1-4)烷基;R和R2独立地是H,卤素,C1-8烷基,C1-8烷氧基,C1-8烷基基,C2-8烯基,C2-8炔基,基或NR3R4,但至少其中之一是NR3R4;R1是卤素,C1-8烷基,C2-8烯基,C2-8炔基,C3-8环烷基,C3-8环烷基(C1-6)-烷基,C1-8烷氧基,C1-8烷基基,芳基,芳氧基,芳基,杂芳基,杂芳氧基,杂芳基,芳基(C1-4)烷基,芳基(C1-4)烷氧基,杂芳基(C1-4)烷基,杂芳基(C1-4)烷氧基,芳基(C1-4)烷基基,杂芳基(C1-4)烷基基,吗啉基,哌啶基吡咯啉基;R3和R4独立地是H,C1-8烷基,C2-8烯基,C2-8炔基,芳基,芳基(C1-8)-烷基,C3-8环烷基,C3-8环烷基(C1-6)-烷基,杂芳基,杂芳基(C1-8)-烷基,NR5R6,但不是R3和R4都是H或NR5R6,或R3和R4一起形成一个C3-7烷基或C3-7烯基链,可选择地用一个或多个C1-4烷基或C1-4烷氧基取代,或与它们所连接的氮原子一起,R3和R4形成吗啉,吗啉,吗啉S-氧化物或吗啉S-二氧化物环或哌嗪哌嗪N-(C1-4)烷基(特别是N-甲基)环;R5和R6独立地是H,C1-8烷基,C2-8烯基,C2-8炔基,芳基,芳基(C1-8)-烷基,C3-8环烷基,C3-8环烷基(C1-6)-烷基,杂芳基或杂芳基(C1-8)-烷基;任何上述烷基,烯基,炔基或环烷基基团(R8除外)可选择地用卤素,基,C1-6烷氧基,C1-6烷基羰基,C1-6烷氧羰基,C1-6卤代烷氧基,C1-6烷基基,三(C1-4)烷基硅烷基,C1-6烷基基或C1-6二烷基基取代,上述任何吗啉,吗啉,哌啶哌嗪吡咯啉环可选择地用C1-4烷基(特别是甲基)取代,上述任何芳基或杂芳基基团可选择地用一个或多个取代基取代,所述取代基选择自卤素,羟基,醇基,C1-6烷基,C2-6烯基,C2-6炔基,C1-6烷氧基,C2-6烯氧基,C2-6炔氧基,卤代(C1-6)烷基,卤代(C1-6)烷氧基,C1-6烷基基,卤代(C1-6)烷基基,羟基(C1-6)烷基,C1-4烷氧基(C1-6)烷基,C3-6环烷基,C3-6环烷基(C1-4)烷基,苯氧基,苄氧基,苯甲酰氧基,基,异氰酸基,硫氰酸基,异硫氰酸基,硝基,-NR''R'',NHCOR'',-NHCONR''R'',-CONR''R'',-SO2R'',-OSO2R'',-COR'',-CR''=NR''或-N=CR''R'',其中R''和R''独立地是氢,C1-4烷基,卤代(C1-4)烷基,C1-4烷氧基,卤代(C1-4)烷氧基,C1-4烷基基,C3-6环烷基,C3-6环烷基(C1-4)烷基,苯基或苄基,苯基和苄基可选择地用卤素,C1-4烷基或C1-4烷氧基取代。
  • Harnden, Michael R.; Jarvest, Richard L., Journal of the Chemical Society. Perkin transactions I, 1991, # 9, p. 2073 - 2080
    作者:Harnden, Michael R.、Jarvest, Richard L.
    DOI:——
    日期:——
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台